Lingdi YIN
EVALUATION OF CIRCULATING TUMOR DNA IN PORTAL VEIN BLOOD AS A BIOMARKER FOR EARLY RECURRENCE OF PANCREATIC CANCER
15:30-15:37 / BP OP 3-1
EVALUATION OF CIRCULATING TUMOR DNA IN PORTAL VEIN BLOOD AS A BIOMARKER FOR EARLY RECURRENCE OF PANCREATIC CANCER
15:30-15:37 / BP OP 3-1
Ryusei MATSUYAMA
SIGNIFICANCE OF CONVERSION SURGERY FOR UNRESECTABLE BILIARY TRACT CANCER
15:37-15:44 / BP OP 3-2
SIGNIFICANCE OF CONVERSION SURGERY FOR UNRESECTABLE BILIARY TRACT CANCER
15:37-15:44 / BP OP 3-2
Seung Soo HONG
THE EFFECT OF PREOPERATIVE RADIOTHERAPY IN THE RESECTABLE PANCREATIC CANCER : A PROSPECTIVE SINGLE CENTER PILOT STUDY
15:44-15:51 / BP OP 3-3
THE EFFECT OF PREOPERATIVE RADIOTHERAPY IN THE RESECTABLE PANCREATIC CANCER : A PROSPECTIVE SINGLE CENTER PILOT STUDY
15:44-15:51 / BP OP 3-3
Aram SHIN
PROPOSAL OF A NOVEL NODAL STAGING SYSTEM FOR RESECTED PANCREATIC CANCER AFTER NEOADJUVANT THERAPY
15:51-15:58 / BP OP 3-4
PROPOSAL OF A NOVEL NODAL STAGING SYSTEM FOR RESECTED PANCREATIC CANCER AFTER NEOADJUVANT THERAPY
15:51-15:58 / BP OP 3-4
Hee Ju SOHN
REVISITING THE SURGICAL STRATEGY OF T1B GALLBLADDER CANCER: A KOREA TUMOR REGISTRY SYSTEM BILIARY PANCREAS (KOTUS-BP) DATABASE ANALYSIS
15:58-16:05 / BP OP 3-5
REVISITING THE SURGICAL STRATEGY OF T1B GALLBLADDER CANCER: A KOREA TUMOR REGISTRY SYSTEM BILIARY PANCREAS (KOTUS-BP) DATABASE ANALYSIS
15:58-16:05 / BP OP 3-5
Pun PUGKHEM
ROLE OF ADJUVANT CHEMOTHERAPY AFTER HEPATIC RESECTION FOR PATIENTS WITH INVASIVE INTRADUCTAL PAPILLARY NEOPLASM OF THE BILE DUCT (IPNB)
16:05-16:12 / BP OP 3-6
ROLE OF ADJUVANT CHEMOTHERAPY AFTER HEPATIC RESECTION FOR PATIENTS WITH INVASIVE INTRADUCTAL PAPILLARY NEOPLASM OF THE BILE DUCT (IPNB)
16:05-16:12 / BP OP 3-6
Hidetaka MIYAZAKI
NEW PATHOLOGICAL RESPONSE SYSTEM; SHRINKAGE PATTERNS FOR RESECTABLE/ BORDERLINE RESECTABLE PANCREATIC CANCERS.
16:12-16:19 / BP OP 3-7
NEW PATHOLOGICAL RESPONSE SYSTEM; SHRINKAGE PATTERNS FOR RESECTABLE/ BORDERLINE RESECTABLE PANCREATIC CANCERS.
16:12-16:19 / BP OP 3-7
Hye-Sol JUNG
OPTIMAL TREATMENT STRATEGY IN PATIENTS WITH SUBOPTIMAL RESPONSE WHO UNDERWENT INDUCTION CHEMOTHERAPY FOR LOCALLY ADVANCED PANCREATIC CANCER (LAPC): TO RESECT OR CONTINUE CHEMOTHERAPY?
16:19-16:26 / BP OP 3-8
OPTIMAL TREATMENT STRATEGY IN PATIENTS WITH SUBOPTIMAL RESPONSE WHO UNDERWENT INDUCTION CHEMOTHERAPY FOR LOCALLY ADVANCED PANCREATIC CANCER (LAPC): TO RESECT OR CONTINUE CHEMOTHERAPY?
16:19-16:26 / BP OP 3-8